Journal of Clinical and
Basic Cardiology
An Independent International Scientific Journal
Journal of Clinical and Basic Cardiology 2006; 9 (1-4), 23-26
Plasma Nitric Oxide Level in Myocardial
Disorders with Left Ventricular Diastolic
Dysfunction
Elshamaa MF, Sharaf EA, Farid YA, Elghoroury EA
Abdelghaffar E
Homepage:
www.kup.at/jcbc
Online Data Base Search
for Authors and Keywords
Indexed in
Chemical Abstracts
EMBASE/Excerpta Medica
Krause & Pachernegg GmbH · VERLAG für MEDIZIN und WIRTSCHAFT · A-3003 Gablitz/Austria
ORIGINAL PAPERS, CLINICAL CARDIOLOGY
J Clin Basic Cardiol 2006; 9 (online): 23
Plasma Nitric Oxide Level
Plasma Nitric Oxide Level in Myocardial Disorders with
Left Ventricular Diastolic Dysfunction
M. F. Elshamaa1, E. A. Sharaf2, Y. A. Farid3, E. A. Elghoroury4, E. Abdelghaffar4
Nitric oxide is a free radical that is elevated in the plasma of patients with heart failure due to contractile dysfunction. This study examines the
relation between plasma NO level and left ventricular (LV) diastolic function and its aetiology in heart failure patients in the pediatric age group.
We performed echocardiographic Doppler studies in 47 patients (mean age 6.16 ± 2.8 years; 31 males and 16 females) with congestive heart
failure. Left ventricular diastolic dysfunction was classified as either a restrictive (RFP) or non-restrictive filling pattern (non-RFP). Same-day
venous total nitrite and nitrate levels were measured by colourimetric assay. Plasma NOx levels were significantly higher in the patient group than
in the control group (141 ± 54 µmol/l and 43 ± 4 µmol/l, respectively; p < 0.001). ROC curves found that the cut-off point for plasma NOx
levels was 60 µmol/l to differentiate between normal children and patients with heart failure. Patients with RFP showed insignificantly higher
levels of plasma NOx than the non-RFP patients (p = n. s.).
Only in muscular dystrophy patients, the correlation between plasma NOx levels and LV ejection fractions (r = –0.61; p = 0.06) and LV
fractional shortenings (r = –0.64; p = 0.04) was negative.
On correlating the plasma NOx levels to the severity of heart failure by multiple linear regression analysis, the pulmonary artery systolic
pressure was the only variable independently associated with an elevated plasma NOx level (p = 0.05).
Plasma NOx levels are elevated in patients with isolated diastolic heart failure. In addition, in patients with LV systolic failure, the severity of
LV diastolic dysfunction determines the amount of NO production. J Clin Basic Cardiol 2006; 9 (online): 23–6.
Key words: nitric oxide, myocardial disorders, heart failure, diastolic dysfunction
N
itric oxide (NO) is a free radical known to be an important determinant of vascular tone. It plays a major role
in the regulation of cardiovascular homeostasis both in important health and disease [1, 2].
Apart from controlling the coronary blood flow, there is
now an emerging consensus that generally acts to fine-tune
and optimise cardiac pump function [1]. Excessive NO depresses systolic function by decreasing myocardial contractility and shortening the ejection period [1]. Elevated circulating levels of oxidative products of (NOx) and myocardial
NO synthetase expression have been seen in patients with
heart failure due to contractile dysfunction [3, 4]. Diastolic
dysfunction commonly co-exists in patients with systolic
heart failure [5]. Nevertheless, some patients experience isolated diastolic heart failure, i.e. heart failure in the setting of
preserved systolic function [6].
This study examines the relation between plasma NO
level and left ventricular (LV) diastolic function and its aetiology in heart failure patients in the pediatric age group.
Three different groups of patients with known chronic diseases of myocardium and abnormal cardiac function (thalassemia, idiopathic dilated cardiomyopathy and muscular dystrophy) were studied.
Methods
Subjects
47 patients (mean age 6.16 ± 2.8 years; 31 males [66 %],
16 females [34 %]) with heart failure (NYHA II–IV) were
studied. 20 healthy children (matching the patients in age
and sex) were also included as a control group for the normal
NO plasma levels.
Patients were recruited from three outpatient clinics of
the Childrens’ Hospital of Cairo University. These clinics
were the hematology clinic (20 patients with thalassemia
[43 %]), the cardiomyopathy clinic (17 patients with idiopathic dilated cardiomyopathy [36 %]), and the myopathy
clinic (10 patients with muscular dystrophy [21 %]).
Patients were maintained on medications such as angiotensin-converting enzyme inhibitors (16 patients [34 %]),
intropics (12 patients [26 %]), diuretics (14 patients [30 %]),
aspirin (5 patients [10.6 %]), L-carnitine (35 patients [74.5 %])
and dysferal (20 [43 %]).
Exclusion Criteria
Patients were excluded if they had a recent history of acute
heart failure in the past 4 weeks, arrhythmia, major organ
dysfunction e.g. renal or hepatic, significant pulmonary disease or systemic illness, malignancy, active infection or inflammatory disease, and acute myocarditis. Written consent
was given by all patients or their parents.
All patients were subjected to complete clinical assessment as well as an electrocardiogram before further evaluation.
Echocardiography
Echocardiography was performed on the same day of blood
sampling for plasma NO. Left ventricular volume indexes at
end-systole and end-diastole were measured by a 2-dimensionally guided M-mode method according to the guidelines
of the American Society of Echocardiography [7]. The ejection fraction was calculated using the modified Simpson’s
rule. Pulse-Doppler assessment of diastolic function was
performed by interrogation of flow velocities at the mitral
annulus [8], and confirmed by pulmonary venous inflow
profile, if necessary [9]. The average of ≥ 3 consecutive beats
was taken. LV diastolic dysfunction was classified as a restrictive filling pattern (RFP) (defined as early to atrial filling
[E/A] ≥ 2 or E/A = 1–2 and deceleration time of early filling
[DT] < 110 ms), or a non-restrictive filling pattern (non-RFP;
Received: November 30th, 2005; accepted: December 20th, 2005.
From the 1Pediatric Department, National Research Center, the 2Pediatric Department, Cairo University, the 3Helwan University, and the 4National
Research Center, Cairo, Egypt.
Correspondence to: Manal Elshamaa, MD, Pediatric Department, National Research Center, Dokki Street, Cairo, Egypt;
e-mail: manal_elshmaa@hotmail.com
For personal use only. Not to be reproduced without permission of Krause & Pachernegg GmbH.
ORIGINAL PAPERS, CLINICAL CARDIOLOGY
J Clin Basic Cardiol 2006; 9 (online): 24
Plasma Nitric Oxide Level
defined as E/A ratio < 1 or E/A = 1–2 and DT > 275 ms,
normal transmitral pattern but abnormal pulmonary venous
flow profile [reverse in systolic to diastolic forward ratio]) [5,
10, 11].
Measurements of Plasma Nitric Oxide Level by
Colourimetric Assay
Plasma nitric oxide level was measured by the nitric oxide
assay kit supplied by Assay Design Inc., Ann Arbor. 2 ml of
venous blood were withdrawn on sodium citrate, centrifuged
at 2,000 g for 10 minutes, and stored at –20 °C until analysis.
The transient and volatile nature of NO makes it unsuitable
for most convenient detection methods, however, two stable
breakdown products, i.e. nitrate (NO3) and nitrite (NO2),
can be easily detected by photometric methods. The technique involves the enzymatic conversion of nitrate to nitrite
by enzyme nitrate reductase followed by colourimetric detection of nitrite as a colored azodye product of the Griesse
reaction [12, 13].
variables. The ROC (receiver operator characteristics) curve
was used to choose a cut-off point to differentiate normal
controls from cases with heart failure. Multiple linear regression analysis was performed with nitric oxide as the dependent variables and systolic, diastolic functions, age, heart rate,
sex and type of dysfunction as independent or covariates.
P-value is significant at 0.05 level.
Results
Statistical Analysis
SPSS (Statistical Package for Social Sciences) version 10.0
was used in data analysis. Mean and standard deviations described quantitative data. Non-parametric ANOVA compared means of > 2 independent groups and Scheffe test
made pairwise comparisons. Pearson’s and Spearman Rho
correlation analyses were performed to predict association of
plasma nitric oxide to cardiac indices and other numerical
According to echocardiographic evaluation, all patients
showed diastolic dysfunction. 17 of them (36.2 %) had impaired systolic (ejection fraction ≤ 50 %) and diastolic functions, while 30 patients (63.8 %) had isolated dysfunction
(Fig. 1). The restrictive filling pattern was observed in 41
patients (26 patients with isolated diastolic dysfunction and
15 patients with systolic and diastolic dysfunction).
Figure 2 shows that plasma NOx levels were significantly
higher in the patient group than the control group (141 ±
54 µmol/l and 43 ± 4 µmol/l, respectively; p < 0.001). ROC
curve found that the cut-off point for plasma NOx levels was
60 µmol/l to differentiate between healthy children and patients with heart failure.
According to Figure 1, patients with RFP showed insignificantly higher levels of plasma NOx than non-RFP patients (p = n. s.).
Table 1 shows the relation between impaired systolic
function and plasma NOx levels in the three aetiologically
Figure 1. Nitric oxide levels according to types of heart failure
Figure 2. Nitric oxide levels among all study groups
Table 1. Correlation between plasma nitric oxide levels and individual systolic and diastolic parameters
Parameters
E-velocity
A-velocity
E/A-ratio
Deceleration time of E
LVEDD
LVESD
LVEF
LVFS
Cardiomyopathy
(n = 17)
r
p-value
0.42
–0.21
0.43
0.30
0.02
0.14
0.04
–0.28
n. s.
n. s.
n. s.
n. s.
n. s.
n. s.
n. s.
n. s.
Muscular dystrophy
(n = 10)
r
–0.13
–0.09
0.03
–0.39
–0.27
–0.28
–0.61
–0.064
Thalassemia
(n = 20)
All groups
(total: 47)
p-value
r
p-value
r
n. s.
n. s.
n. s.
n. s.
n. s.
n. s.
0.06*
0.04*
–0.27
–0.52
0.07
0.08
–0.30
–0.27
0.17
0.18
n. s.
0.2
n. s.
n. s.
n. s.
n. s.
n. s.
n. s.
–0.03
–0.29
–0.20
–0.004
–0.05
0.05
–0.08
–0.19
p-value
n. s.
n. s.
n. s.
n. s.
n. s.
n. s.
n. s.
n. s.
E-velocity = transmitral peak early-filling velocity; A-velocity = transmitral peak atrial filling velocity; E/A-ratio = ratio of transmitral peak early to
atrial filling velocity; LVEDD = left ventricular end-diastolic dimension; LVESD = left ventricular end-systolic dimension; LVEF = left ventricular
ejection fraction; LVFS = left ventricular fractional shortening; *p < 0.05 was considered significant
ORIGINAL PAPERS, CLINICAL CARDIOLOGY
J Clin Basic Cardiol 2006; 9 (online): 25
Plasma Nitric Oxide Level
Table 2. Multiple linear regression analysis comparing the correlation
between plasma nitric oxide level and individual variables
Varibale
E-velocity
A-velocity
E/A-ratio
Deceleration time of E
LVEDD
LVESD
PASP
Age
Sex
Heart rate
beta
p-value
–0.78
0.29
0.88
0.01
–0.46
1.50
–0.29
–0.02
0.13
0.08
0.14
0.54
0.19
0.96
0.19
0.13
0.05*
0.09
0.39
0.66
* p < 0.05 was considered significant; PASP = pulmonary artery
systolic pressure; for other abbreviations see Table 1
different heart failure patients. Only in muscular dystrophy
patients, there were negative correlations between plasma
NOx level and LV ejection fraction (r = –0.61; p = 0.06) and
LV fractional shortening (r = –0.64; p = 0.04).
Table 2: on correlating the plasma NOx levels to the severity of heart failure by multiple linear regression analysis,
the pulmonary artery systolic pressure was the only variable
independently associated with an elevated plasma NOx level
(p = 0.05).
There was no significant correlation of plasma level of
NOx and either the aetiology of heart failure (Fig. 2) or the
medications received by the patients.
Discussion
There is now good evidence that NO has important
autocrine/paracrine effects in the myocardium, in general
serving to optimize and fine-tune the cardiac function
through actions on inotrope stat, excitation-contraction coupling, diastolic function, heart rate, and beta-adrenergic responsiveness. It is clear that the biological activity of NO is
altered during human heart failure [14].
In our study, there was a significant elevation of plasma
NO levels in patients with isolated LV diastolic dysfunction,
as well as those with combined systolic and diastolic dysfunction. It also showed that the coexisting severity of LV diastolic
dysfunction, rather than LV systolic dysfunction itself, correlates with plasma NOx level. Patients with RFP had higher
plasma NOx levels than those with non-RFP. On the ROC
curve, the cut-off point of plasma NOx levels was at
152 µmol/l to differentiate between RFP and a non-RFP
patients. All patients above this level had a RFP. RFP is more
prevalent in systolic heart failure with left ventricular
diastolic dysfunction.
It signifies more advanced heart failure with higher filling
pressure and decreased compliance in both left atrial and left
ventricle, as well as a worse prognosis [6, 9].
The elevation of circulating NOx could be a consequence
of increased cardiac production, as NO is carried away by
hemoglobin as well as by the amino acid, glutathione, and
cysteine. It has been demonstrated that there is beat-to-beat
cardiac NO production in response to mechanical stimuli
which is maximal at the mid-diastole in isolated heart preparation [15].
In the heart, microvascular and endocardial cells were the
main sources of load-dependent cardiac NO, through the
activation of endothelial NO synthase [15, 16]. There is
evidence that the stable end product of NO (i.e. nitrate) is
significantly increased in patients with chronic heart failure
[3]. In an in vitro study, inducible NO synthase expression
was found to be increased in ventricular myocytes isolated
from the severely failing heart [4].
In one study, patients with mild to severe heart failure underwent right and left heart catherization [17]. The generation of NOx confirmed by the increase in the level in the
coronary sinus, and therefore, the difference between coronary sinus and ascending aorta [17]. These studies confirmed
the cardiac source of production of NO in systolic heart failure, its correlation with coexisting diastolic dysfunction and
overproduction of NO in isolated diastolic heart failure have
not been demonstrated.
In conjunction with the results of the present study it has
been speculated that elevation of plasma NOx in patients
with heart failure, especially in those with isolated diastolic
heart failure, is a compansatory response to the elevated LV
filling pressure. This is supported by the fact that the basal
cardiac secretion of NO is important in the maintenance of
diastolic function [2], as well as infusion of NO to patients
with LV hypertrophy, which has beneficial hemodynamic effects on the parameters of diastolic function [2, 18].
In contrast, depending on the amount and mechanism of
NO production, excess NO production can be detrimental
to the heart. Studies have found that cytokine-inducible NO
synthase was expressed in cardiac myocytes with contractile
failure of various etiologies and overproduction of NO is
likely a result [2, 19].
Excessive NO has been shown to depress contractile
function, can be cytotoxic and can induce apoptosis. Immunological response to heart failure results in endothelial and
myocyte dysfunction through oxidative stress-mediated apoptosis [20]. These events, however, are unlikely to occur in
isolated diastolic heart failure in which contractile function is
preserved and myocyte damage is minimal. Other than the
ventricle, atrial production of NO can not be excluded as the
plasma NOx level has also been found to correlate with left
atrial size [2]. Lastly, NO may also be synthesized from noncardiac sources, such as in skeletal muscles of patients with
severe systolic heart failure [21]. Peripheral vascular endothelial NO production does not account for these changes, as
endothelial dysfunction secondary to reduced endothelial
NO synthesis had been previously described [22].
Regarding the speculated role of NO in heart failure, NOtargeted therapy is a potentially useful therapeutic modality
in these patients, which is exemplified by the use of NO in
LV hypertrophy [17]. Inhaled nitric oxide has shown promise
for acute right ventricular failure [23]. L-NG-mono methylarginine (L-NMMA), an NOS inhibitor, blocks negative
inotropic effects of NO and aminoguanidine (a selective inducible NO synthase inhibitor) is used in early cardiac allograft rejection [24]. The different mechanisms by which NO
results in these contrasting effects seen in CHF may involve
decreases and increases in oxidative stress, respectively.
Acknowledgements
Our work was supported by the National Research Center,
Cairo, Egypt.
References:
1. Cotton JM, Kearney MT, Shah AM. Nitric oxide and myocardial function in
heart failure: friend or foe? Heart 2002; 88: 564–6.
2. Mitsuke Y, Lee JD, Shimizu H, Uzui H, Iwasaki H, Ueda T. Nitric oxide
synthase activity in peripheral polymorphonuclear leukocytes in patients with
chronic congestive heart failure. Am J Cardiol 2001; 87: 183–7.
3. Balat A, Cekmen M, Yurekli M, Yilmaz K, Sahinoz S. Adrenomodulin and
nitrite in children with dilated cardiomyopathy. Pediatric Cardiol 2003; 24:
381–5.
ORIGINAL PAPERS, CLINICAL CARDIOLOGY
J Clin Basic Cardiol 2006; 9 (online): 26
4. Fukuchi M, Hussain S, Giaid A. Heterogenous expression and activity of endothelial and inducible nitric oxide synthases in end stage human heart failure. Circulation 1998; 19: 132–9.
5. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic
heart failure – part 2: diagnosis, prognosis, and measurements of diastolic dysfunction. Circulation 2002; 105: 1387–93.
6. Diasp P, Rodrigues RA, Oueiros MC, Monleiro E, Pereira M. Prognosis in
patients with heart failure and preserved left ventricular systolic function. Rev
Port Cardiol 2001; 20: 1223–32.
7. Rodrigues RA, Diasp P, Pereira M, Oueiros MC, Monleiro E. Echocardiographic patterns and prognosis in heart failure. Rev Port Cardiol 2001; 20:
1241–6.
8. Yu CM, Lin FH, Yang H, Kong SH, Zhang Q, Lee WL. Progression of systolic
abnormalities in patients with isolated diastolic heart failure and diastolic dysfunction. Circulation 2002; 105: 1195–201.
9. Erbel R, Neumann T, Zeidan Z, Bartel T, Buck T. Echocardiographic diagnosis of diastolic heart failure. Herz 2002; 27: 99–106.
10. Park MK. Primary myocardial disease. In: Pediatric Cardiology. 3rd ed.
Mosby-Year Book Inc., St. Louis, 1992.
11. Vasan RS, Levy D. Defining diastolic heart failure: a call for standarized diagnostic criteria. Circulation 2002; 101: 2118-21.
12. Akiyama K, Suzuki H, Grant P, Bing RJ. Oxidation products of nitric oxide,
NO2 and NO3, in plasma after experimental myocardial infarction. J Mol
Cell Cardiol 1997; 29: 1–9.
13. Sheu FS, Zhu W, Fung PC. Direct observation of trapping and release of nitric
oxide by glutathione and cysteine with electron paramagnetic resonance
spectroscopy. Biophys 2000; 78: 1216–26.
14. Cheuk-Man Y, Fung P, Chan G, Lai KWH, Wang Q, Lau CP. Plasma nitric
oxide level in heart failure secondary to left ventricular diastolic dysfunction.
Am J Cardiol 2001; 88: 867–70.
Plasma Nitric Oxide Level
15. Pinsky DJ, Patton S, Mesaros S, Brovkovych H, Kubazewski E, Grunfeld S,
Maliniski T. Mechanical transduction of nitric oxide synthesis in the beating
heart. Circ Res 1997; 81: 372–9.
16. Stefan D, Stephan VH. Inflammatory mediators in chronic heart failure: an
overview. Heart 2004; 90: 464–70.
17. Node K, Kilakaze M, Yoshihara F, Sasaki T, Kuzuya T, Hori M. Increased
cardiac levels of nitric oxide in patients with chronic heart failure. Am
J Cardiol 2000; 86: 474–7.
18. Matter CM, Mandinov L, Kaufmann PA, Vassalli G, Jiang Z, Hess OM. Effect
of NO donors on LV diastolic function in patients with severe pressure-overload hypertrophy. Circulation 1999; 99: 2396–401.
19. Thibaud D, Philippe R, Ajay M, Emmanuel C, Isabelle M, Hassenfuss G,
Marotti F, Samuel JL, Heymes C. Increased neuronal nitric oxide synthasederived NO production in the failing human heart. Lancet 2004; 363: 1365–7.
20. Ferrari R, Guardigli G, Mele D, Percoco GF, Ceconi C, Curello S. Oxidative
stress during myocardial ischemia and heart failure. Curr Pharm Des 2004;
10: 1699–711.
21. Riede UN, Forstermann U, Drexler H. Inducible nitric oxide synthase in
skeletal muscle of patients with chronic heart failure. J Am Coll Cardiol 1999;
32: 964–9.
22. Katz SD. Mechanisms and implications of endothelial dysfunction in congestive heart failure. Curr Opin Cardiol 1997; 12: 259–64.
23. Wasson S, Govindarajan G, Reddy HK, Flaker G. The role of nitric oxide and
vasopressin in refractory right heart failure. J Cardiovascpharm Ther 2004; 9:
9–11.
24. Worrall NK, Pyo RT, Botney M, Misko TP, Sullivan PM, Alexander DG,
Lazenby WD, Ferguson TB. Inflammatory cell derived NO modulates cardiac allograft contractile and electrophysiological function. Am J Physiol
1997; 273: H28–H37.